"Both children showed rapid normalization of their LV ejection fraction and B-type
natriuretic protein as well as improvement in D-dimer that were temporally-associated with
remestemcel-L treatment (Figure 1). In addition, serial echocardiographic imaging showed
reduction in the severity of pan-valvular regurgitation as well as increases in LV end systolic
volume. The latter observation is consistent with improvement in LV contractile state that was
temporally-associated with the cell therapy administration"
Doesn't sound like that was consistent with the previous gradual improvement they were showing - disclaimer 'I'm not a doctor'
Ann: Remestemcel-L for COVID-19 MIS-C published in Pediatrics, page-47
-
- There are more pages in this discussion • 377 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
0.000(0.00%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 539 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 10643 | 1 |
View Market Depth
| Last trade - 09.51am 16/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |
Day chart unavailable